ES2513915T3 - Inhibidores de la tirosina quinasa de Bruton - Google Patents

Inhibidores de la tirosina quinasa de Bruton Download PDF

Info

Publication number
ES2513915T3
ES2513915T3 ES10714295.2T ES10714295T ES2513915T3 ES 2513915 T3 ES2513915 T3 ES 2513915T3 ES 10714295 T ES10714295 T ES 10714295T ES 2513915 T3 ES2513915 T3 ES 2513915T3
Authority
ES
Spain
Prior art keywords
alkyl
hydroxy
halogen
alkoxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10714295.2T
Other languages
English (en)
Spanish (es)
Inventor
Nolan James Dewdney
Ronald Charles Hawley
Rama K. Kondru
Yingjie Lai
Yan Lou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2513915T3 publication Critical patent/ES2513915T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES10714295.2T 2009-04-24 2010-04-21 Inhibidores de la tirosina quinasa de Bruton Active ES2513915T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17228809P 2009-04-24 2009-04-24
US172288P 2009-04-24
PCT/EP2010/055227 WO2010122038A1 (en) 2009-04-24 2010-04-21 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
ES2513915T3 true ES2513915T3 (es) 2014-10-27

Family

ID=42235672

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10714295.2T Active ES2513915T3 (es) 2009-04-24 2010-04-21 Inhibidores de la tirosina quinasa de Bruton

Country Status (8)

Country Link
US (1) US8318719B2 (de)
EP (1) EP2421854B1 (de)
JP (1) JP5497152B2 (de)
CN (1) CN102292329B (de)
CA (1) CA2748414A1 (de)
ES (1) ES2513915T3 (de)
SG (1) SG175287A1 (de)
WO (1) WO2010122038A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
US8975260B2 (en) 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
JP5826863B2 (ja) * 2011-02-15 2015-12-02 イミュノジェン・インコーポレーテッド 細胞傷害性ベンゾジアゼピン誘導体
CA2836669C (en) * 2011-05-20 2019-03-19 Glaxosmithkline Intellectual Property (No.2) Limited Compounds as diacylglycerol acyltransferase inhibitors
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005282A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de 8-fluoroftalazin-1 (2h) -ona.
EP2773639B1 (de) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylierte piperazin-verbindungen als inhibitoren von btk aktivität
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
EP2964642B1 (de) * 2013-03-05 2017-11-15 F. Hoffmann-La Roche AG Hemmer der bruton-tyrosinkinase
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CA2902686C (en) 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
WO2015000949A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2015082583A1 (en) 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3042903B1 (de) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituierte heterobicyclische Verbindungen, Zusammensetzungen und medizinische Anwendungen davon
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
IL292938A (en) 2016-09-19 2022-07-01 Mei Pharma Inc Combined treatment
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
EP3645569A4 (de) 2017-06-26 2021-03-24 BeiGene, Ltd. Immuntherapie für leberzellkarzinom
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
MX2007011041A (es) * 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
CN101835755B (zh) * 2007-10-23 2013-12-11 霍夫曼-拉罗奇有限公司 激酶抑制剂
PL2242749T3 (pl) * 2008-02-05 2013-09-30 Hoffmann La Roche Nowe pirydynony i pirydazynony
PH12012502374A1 (en) * 2008-06-24 2014-11-12 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
PE20110164A1 (es) * 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa

Also Published As

Publication number Publication date
JP2012524748A (ja) 2012-10-18
US20100273768A1 (en) 2010-10-28
CN102292329B (zh) 2014-09-03
EP2421854A1 (de) 2012-02-29
CN102292329A (zh) 2011-12-21
CA2748414A1 (en) 2010-10-28
SG175287A1 (en) 2011-11-28
US8318719B2 (en) 2012-11-27
WO2010122038A1 (en) 2010-10-28
EP2421854B1 (de) 2014-07-23
JP5497152B2 (ja) 2014-05-21

Similar Documents

Publication Publication Date Title
ES2513915T3 (es) Inhibidores de la tirosina quinasa de Bruton
ES2461494T3 (es) Nuevas fenilimidazopirazinas
ES2420854T3 (es) Nuevas fenilpirazinonas como inhibidores de quinasas
TWI382024B (zh) 新穎之吡啶酮及嗒酮
KR101585753B1 (ko) 브루톤 티로신 키나아제의 억제제
CA2728016C (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
RU2610840C2 (ru) Тиазолопиримидины
KR20150054994A (ko) 브루톤 티로신 키나아제의 억제제
KR101768402B1 (ko) 브루톤 티로신 키나제의 억제제
KR20150113195A (ko) 브루톤 티로신 키나아제의 억제제
ES2607635T3 (es) Derivados tiazol como inhibidores de tirosina quinasa de Bruton
BR112016013540B1 (pt) inibidores de tirosina quinase de bruton
KR101822767B1 (ko) 브루톤 티로신 키나아제의 억제제
KR101737723B1 (ko) 브루톤 티로신 키나아제의 억제제
RU2618529C2 (ru) Ингибиторы тирозинкиназы брутона
HK1212975B (en) Thiazole derivatives as inhibitors of bruton's tyrosine kinase